UroGen Pharma Ltd Cash Flow Reinvestment Rate

Latest as of September 2017: 13.87x

UroGen Pharma Ltd cash flow reinvestment rate. UroGen Pharma Ltd (URGN) has a Cash Flow Reinvestment Rate of 13.87x as of September 2017, reinvesting $36.02 Million (capex $20.00K plus investments $-36.00 Million) from operating cash flow of $2.60 Million. Explore URGN operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

13.87x

(Capex + Investments) / Operating CF

Total Reinvested

$36.02 Million

Capex + Investments

Operating Cash Flow

$2.60 Million

USD

Capital Expenditures

$20.00K

USD

Cash Flow Reinvestment Rate of UroGen Pharma Ltd (2016–2016)

Cash flow reinvestment rate of UroGen Pharma Ltd from 2016 to 2016. Historical reinvestment intensity for UroGen Pharma Ltd across 1 annual periods. Explore URGN capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.

UroGen Pharma Ltd Cash Flow Reinvestment Rate by Year (2016–2016)

UroGen Pharma Ltd cash flow reinvestment rate by year from 2016 to 2016. Year-by-year capital reinvestment analysis for UroGen Pharma Ltd. For the full cash flow conversion analysis, see URGN cash flow conversion.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2016	0.36x	$1.49 Million	$4.19 Million	$695.00K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow